676 related articles for article (PubMed ID: 19709880)
21. Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives.
Tian Y; Du D; Rai D; Wang L; Liu H; Zhan P; De Clercq E; Pannecouque C; Liu X
Bioorg Med Chem; 2014 Apr; 22(7):2052-9. PubMed ID: 24631361
[TBL] [Abstract][Full Text] [Related]
22. Scaffold hopping in the rational design of novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
O'Meara JA; Jakalian A; LaPlante S; Bonneau PR; Coulombe R; Faucher AM; Guse I; Landry S; Racine J; Simoneau B; Thavonekham B; Yoakim C
Bioorg Med Chem Lett; 2007 Jun; 17(12):3362-6. PubMed ID: 17451954
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological activity of naphthyl-substituted (B-ring) benzophenone derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
Ma XD; Zhang X; Dai HF; Yang SQ; Yang LM; Gu SX; Zheng YT; He QQ; Chen FE
Bioorg Med Chem; 2011 Aug; 19(15):4601-7. PubMed ID: 21719299
[TBL] [Abstract][Full Text] [Related]
24. The effect of NNRTIs on HIV reverse transcriptase dimerization.
Tachedjian G; Goff SP
Curr Opin Investig Drugs; 2003 Aug; 4(8):966-73. PubMed ID: 14508881
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.
Gu SX; Yang SQ; He QQ; Ma XD; Chen FE; Dai HF; Clercq ED; Balzarini J; Pannecouque C
Bioorg Med Chem; 2011 Dec; 19(23):7093-9. PubMed ID: 22037050
[TBL] [Abstract][Full Text] [Related]
26. The design and synthesis of N-1-alkylated-5-aminoarylalkylsubstituted-6-methyluracils as potential non-nucleoside HIV-1 RT inhibitors.
Lu X; Chen Y; Guo Y; Liu Z; Shi Y; Xu Y; Wang X; Zhang Z; Liu J
Bioorg Med Chem; 2007 Dec; 15(23):7399-407. PubMed ID: 17870545
[TBL] [Abstract][Full Text] [Related]
27. Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex.
Samuele A; Kataropoulou A; Viola M; Zanoli S; La Regina G; Piscitelli F; Silvestri R; Maga G
Antiviral Res; 2009 Jan; 81(1):47-55. PubMed ID: 18984007
[TBL] [Abstract][Full Text] [Related]
28. Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 13: synthesis of fluorine-containing diaryltriazine derivatives for in vitro anti-HIV evaluation against wild-type strain.
Xiong YZ; Chen FE; Balzarini J; De Clercq E; Pannecouque C
Chem Biodivers; 2009 Apr; 6(4):561-8. PubMed ID: 19353537
[TBL] [Abstract][Full Text] [Related]
29. Pyrimidine thioethers: a novel class of HIV-1 reverse transcriptase inhibitors with activity against BHAP-resistant HIV.
Nugent RA; Schlachter ST; Murphy MJ; Cleek GJ; Poel TJ; Wishka DG; Graber DR; Yagi Y; Keiser BJ; Olmsted RA; Kopta LA; Swaney SM; Poppe SM; Morris J; Tarpley WG; Thomas RC
J Med Chem; 1998 Sep; 41(20):3793-803. PubMed ID: 9748354
[TBL] [Abstract][Full Text] [Related]
30. Diphenyl ether non-nucleoside reverse transcriptase inhibitors with excellent potency against resistant mutant viruses and promising pharmacokinetic properties.
Sweeney ZK; Kennedy-Smith JJ; Wu J; Arora N; Billedeau JR; Davidson JP; Fretland J; Hang JQ; Heilek GM; Harris SF; Hirschfeld D; Inbar P; Javanbakht H; Jernelius JA; Jin Q; Li Y; Liang W; Roetz R; Sarma K; Smith M; Stefanidis D; Su G; Suh JM; Villaseñor AG; Welch M; Zhang FJ; Klumpp K
ChemMedChem; 2009 Jan; 4(1):88-99. PubMed ID: 19006142
[TBL] [Abstract][Full Text] [Related]
31. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
[TBL] [Abstract][Full Text] [Related]
32. Computational strategies in discovering novel non-nucleoside inhibitors of HIV-1 RT.
Barreca ML; Rao A; De Luca L; Zappalà M; Monforte AM; Maga G; Pannecouque C; Balzarini J; De Clercq E; Chimirri A; Monforte P
J Med Chem; 2005 May; 48(9):3433-7. PubMed ID: 15857150
[TBL] [Abstract][Full Text] [Related]
33. Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors.
Pelemans H; Esnouf R; De Clercq E; Balzarini J
Mol Pharmacol; 2000 May; 57(5):954-60. PubMed ID: 10779379
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and studies of new 2-(coumarin-4-yloxy)-4,6-(substituted)-S-triazine derivatives as potential anti-HIV agents.
Mahajan DH; Pannecouque C; De Clercq E; Chikhalia KH
Arch Pharm (Weinheim); 2009 May; 342(5):281-90. PubMed ID: 19415671
[TBL] [Abstract][Full Text] [Related]
35. Slow-, tight-binding HIV-1 reverse transcriptase non-nucleoside inhibitors highly active against drug-resistant mutants.
Cancio R; Mai A; Rotili D; Artico M; Sbardella G; Clotet-Codina I; Esté JA; Crespan E; Zanoli S; Hübscher U; Spadari S; Maga G
ChemMedChem; 2007 Apr; 2(4):445-8. PubMed ID: 17323401
[No Abstract] [Full Text] [Related]
36. Synthesis and biological evaluation of (±)-benzhydrol derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
Ma XD; Zhang X; Yang SQ; Dai HF; Yang LM; Gu SX; Zheng YT; He QQ; Chen FE
Bioorg Med Chem; 2011 Aug; 19(16):4704-9. PubMed ID: 21788138
[TBL] [Abstract][Full Text] [Related]
37. Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
Fattorusso C; Gemma S; Butini S; Huleatt P; Catalanotti B; Persico M; De Angelis M; Fiorini I; Nacci V; Ramunno A; Rodriquez M; Greco G; Novellino E; Bergamini A; Marini S; Coletta M; Maga G; Spadari S; Campiani G
J Med Chem; 2005 Nov; 48(23):7153-65. PubMed ID: 16279773
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.
Chen X; Zhan P; Liu X; Cheng Z; Meng C; Shao S; Pannecouque C; De Clercq E; Liu X
Bioorg Med Chem; 2012 Jun; 20(12):3856-64. PubMed ID: 22591854
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and biological evaluation of 6-substituted 5-alkyl-2-(phenylaminocarbonylmethylthio)pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs.
Yu M; Li Z; Liu S; Fan E; Pannecouque C; De Clercq E; Liu X
ChemMedChem; 2011 May; 6(5):826-33. PubMed ID: 21322110
[TBL] [Abstract][Full Text] [Related]
40. Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
Butini S; Brindisi M; Cosconati S; Marinelli L; Borrelli G; Coccone SS; Ramunno A; Campiani G; Novellino E; Zanoli S; Samuele A; Giorgi G; Bergamini A; Di Mattia M; Lalli S; Galletti B; Gemma S; Maga G
J Med Chem; 2009 Feb; 52(4):1224-8. PubMed ID: 19170521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
